

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



1 2 3 4 5 6




FIG. 1



1 2 3 4 5




FIG. 2



1 2 3 4 5 6




FIG. 3





FIG. 4




FIG. 5



FDCPmix proliferation inhibition by
INPROL: direct effect *in vitro*




FIG. 6



INPROL affects dynamic of CFU-S proliferation inhibition





FIG. 7

FIG. 8

**INPROL injected *in vivo* protects mice
from the lethal duble 5FU treatment**





**Survival of lethally irradiated
mice after treatment with INPROL**




FIG. 9



**Cell regeneration in BMLTC - L1210 cultures
after combined AraC plus Inprol treatment**




FIG. 10A



**Cell regeneration in BMLTC - L1210 cultures
after combined AraC plus Inprol treatment**




FIG. 1OB



30 days radioprotection by the bone marrow cells
after preincubation with (B) or without (A) INPROL




FIG. 11



**Marrow repopulating ability of BDF1
mice cells after incubation with INPROL**




FIG. 12



**Pre-B progenitors number in Lymphoid Long Term Culture
after preincubation with or without INPROL**




FIG. 13



INPROL improves the repopulating ability
(LTC-IC number) of leukemic peripheral blood cells





FIG. 14





FIG. 15A



Analysis: Channel A

Peak No.	Time	Type	Height(μ Y)	Area(μ Y-sec)	Area%
1	3.126	N1	691	7578	0.041
2	3.315	N2	1011	5150	0.027
3	49.618	N	8584	349227	1.893
4	51.298	N	1456	20274	0.109
5	52.673	N1	138069	2633395	14.278
6	53.148	N2	271587	14050458	76.181
	54.935	N3	33016	1332820	7.226
	67.595	N	3270	44507	0.241
TOTAL AREA				18443409	99.996



Analysis: Channel A

Peak No.	Time	Type	Height(μ Y)	Area(μ Y-sec)	Area%
1	4.383	N1	3945	95125	0.119
2	5.080	N2	28639	330889	0.413
3	5.216	N3	49084	531867	0.665
4	7.980	N1	399424	1110511	1.389
5	8.100	Err	1203320	2882013	3.605
6	8.241	N3	443249	1506159	1.884
7	8.386	N4	481563	2185702	2.734
8	8.533	N5	412886	1826165	2.284
9	8.701	N6	321500	842122	1.053
10	8.745	N7	404661	1610380	2.014
11	8.995	N8	435765	2489721	3.114
12	9.316	N9	517790	4801831	6.007

FIG. 15B





FIG. 15C




FIG. 16B

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Val His Leu Thr Pro Glu Glu Lys Ser Ala Val Thr Ala Leu Trp Gly Lys Val Asn Val
CTG CAC ACT CCT GAG CAG AAG TCT GCC GTT ACT GCC CTG TGG GGT AAC GTG AAC GTG

21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
Asp Glu Val Gly Glu Ala Leu Gly Arg Leu Leu Val Val Trp Pro Trp Thr Gln Arg
CAT GAA GTT GGT GAG GCC CTG GGC AGG CTG CTG GTC TAC CTT TGG ACC CAC AGG

41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Phe Phe Glu Ser Phe Gly Asp Leu Ser Thr Pro Asp Ala Val Met Gly Asn Pro Lys Val
TTC TTT GAG TCC TTT GCG CAT CTG TCC ACT CCT CAT CCT GTT ATG GGC AAC CCT AAC GTG

61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80
Lys Ala His Gly Lys Lys Val Leu Gly Ala Phe Ser Asp Gly Leu Ala His Leu Asp Asn
AAG CCT CAT GCC AAG AAA CTG CTC GGT GCC TTT ACT GAT GCC CTG CCT CAC CTG CAC AAC

81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100
Leu Lys Gly Thr Phe Ala Thr Leu Ser Glu Leu His Cys Asp Lys Leu His Val Asp Pro
CTC AAG GGC ACC TTT GCC ACA CTG AGT CAG CTG CAC TCT CAC AAC CTG CAC CTG CAT CCI

101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
Glu Asn Phe Arg Leu Leu Gly Asn Val Leu Val Cys Val Leu Ala His His Phe Gly Lys
GAG AAC TTC ACG CTG CTG GCG AAC CTG CTG TCT TCT CTG GGC CAT CAC TTT GGC AAA

121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140
Glu Phe Thr Pro Pro Val Gln Ala Ala Tyr Gln Lys Val Val Ala Gly Val Ala Asn Ala
GAA TTC ACC CCA CCA CTG CAG GCT GCC TAT CAG AAA GTC GTC GGT GGT GGT AAT GCC

141 142 143 144 145 146
Leu Ala His Lys Tyr His
CTG GCC CAC AAG TAT CAC



FIG. 16C

hHemA.pep	1	V-LSPADKIN	10	VKAAGKVG	20	HA-GEYGAE	30	LE-RMFLSFP	40	TTKTYFFPHF-	50
hHemB.pep	1	VHLTPEEKSA		VTALWGKV--		-NVDEVGGEA		LG-RLLVVYP		WTQRRFFESFG	50
mHemA.pep	1	V-LSGEDKSN		IKAAWGKIGG		HG-AEYGAEA		LE-RMFASFP		TTKTYFFPHF-	50
mHemB.pep	1	VHLTDAEKAA		VSCSWGKVNS		D---EVGGEA		L-GRLLVVYP		WTQRYFDSFG	50
pHemA.pep	1	V-LSAADKAN		VKAAGKVG		QA-GAHGAEA		LE-RMFLGFP		TTKTYFFPHF-	50
pHemB.pep	1	VHLSAEEKEA		VLGLWGKVN		D---EVGGEA		L-GRLLVVYP		WTQRRFFESFG	50
hHemA.pep	51	DLSH-----G	60	SAQVKGHGKK	70	VADALTN---	80	AVAHVDDMPN	90	ALS--ALSDL	100
hHemB.pep	51	DLSTPDVAVMG		NPVKAHGKK		VLGA---FSD		GLAHLNKG		TFA--TLSEL	100
mHemA.pep	51	DVSH-----G		SAQVKGHGKK		VADALAS---		AAGHLDDLP		ALS--ALSDL	100
mHemB.pep	51	DLSSASAIMG		NAKVAHGKK		V---ITAFND		GLNHLDSLKG		TFASL--SEL	100
pHemA.pep	51	NLSH-----G		SDQVKAHGQK		VADALTK---		AVGHLDDLP		ALS--ALSDL	100
pHemB.pep	51	DLSNADAVMG		NPVKAHGKK		V---LQSFSD		GLKHLNKG		TFAKL--SEL	100
hHemA.pep	101	HAHKLVRVDPV	110	NFKLLSHCLL	120	VTLAAHLPAE	130	FTPAVHASLD	140	-KFLASVSTV	150
hHemB.pep	101	HCDKLHVDPE		NFRLLGNVLV		CVLAHFFGKE		FTPPVQAAYQ		-KVVAGVANA	150
mHemA.pep	101	HAHKLVRVDPV		NFKLLSHCLL		VTLASHHPAD		FTPAVHASLD		-KFLASVSTV	150
mHemB.pep	101	HCDKLHVDPE		NFRLLGNMIV		IVLGHHLGKD		FTPAAQAAF-		QKVVAGVATA	150
pHemA.pep	101	HAHKLVRVDPV		NFKLLSHCLL		VTLAAHHPDD		FNPSVHASLD		-KFLANVSTV	150
pHemB.pep	101	HCDQLHVDPE		NFRLLGNVIV		VVLARRLGH		FNPDVQAAF-		QKVVAGVANA	150
hHemA.pep	151	LTSKYR....	160	170	180	190	200
hHemB.pep	151	LAHKYH....		200
mHemA.pep	151	LTSKYR....		200
mHemB.pep	151	LAHKYH....		200
pHemA.pep	151	LTSKYR....		200
pHemB.pep	151	LAHKYH....		200




FIG. 17A

Analysis Channel A

Peak No.	Time	Type	Height(μY)	Area (μY-sec)	Area %
1	48.200	N	1677	20438	1.515
2	52.076	N1	7625	116393	8.631
3	52.510	N2	32010	881490	65.369
4	53.660	N3	10066	330153	24.483
Total Area				1348474	99.998




FIG. 17B

Analysis Channel A

Peak No.	Time	Type	Height(μY)	Area (μY-sec)	Area %
1	47.110	N1	1727	24840	0.204
2	47.723	N2	75067	1738939	14.321
3	49.153	N3	188795	6206410	51.114
4	52.250	N1	81476	3046748	25.092
5	52.115	N2	13195	202166	1.664
6	53.613	N3	19211	914954	7.535
	65.753	N	818	8066	0.066
Total Area				12142123	99.996




FIG. 18




FIG. 19A




FIG. 19B

FIG. 20

Comparison of Inprol and Hemoglobin Chains in FDPCmix Assay







FIG. 21






FIG. 22A




FIG. 22B




FIG. 22C




FIG. 23